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Wilms' tumorely conserved amongst placental mammals. Imprinted expression of IGF2R,
however, differs between mice and humans. In mice, Igf2r imprinted expression is seen in all fetal and adult
tissues. In humans, adult tissues lack IGF2R imprinted expression, but it is found in fetal tissues and Wilms'
tumors where it is polymorphic and only seen in a small proportion of tested samples. Mouse Igf2r imprinted
expression is controlled by the Air (Airn) ncRNA whose promoter lies in an intronic maternally-methylated
CpG island. The human IGF2R gene carries a homologous intronic maternally-methylated CpG island of
unknown function. Here, we use transfection and transgenic studies to show that the human IGF2R intronic
CpG island is a ncRNA promoter. We also identify the same ncRNA at the endogenous human locus in 16–40%
of Wilms' tumors. Thus, the human IGF2R gene shows evolutionary conservation of key features that control
imprinted expression in the mouse.
© 2008 Elsevier Inc. All rights reserved.Introduction
Genomic imprinting is an epigenetic process that leads to parental-
speciﬁc expression in diploid cells [1,2]. Inmammals, genomic imprinting
affects approximately 80 autosomal genes that are mostly grouped into
small clusters [3,4]. Imprinted gene expression has been identiﬁed in
diverse mammals and, with the exception of egg-laying mammals, may
be conserved in all mammalian classes — reinforcing a proposed link
between genomic imprinting and maternal control of fetal growth [5].
Despite this general conservation amongst mammals, many genes have
been identiﬁed that lack conserved imprinted expression between mice
and humans [6]. This has been suggested to be an adaptation to different
reproductive strategies in human monotoccus (i.e., single offspring) and
mouse polytoccus (i.e., multiple offspring) pregnancies [7].
The mouse Igf2r (insulin-like growth factor type 2 receptor) gene is
part of an imprinted cluster spanning 500 kb on chromosome 17, that
contains three maternally-expressed protein-coding genes (Igf2r,
Slc22a2 and Slc22a3), and, one paternally-expressed ncRNA (Air,
named from Antisense to Igf2r RNA Noncoding) [8]. Despite the
extensive synteny of this region between mice and humans (http://
www.ensembl.org), imprinted expression differs. In mice, Igf2r and Air
show ubiquitous imprinted expression in fetal, extra-embryonic andlow).
ecology, Medical University of
l rights reserved.adult tissues with the exception of post-mitotic neurons [9], while
Slc22a2 and Slc22a3 show imprinted expression only in placenta in a
temporally-regulated manner [10]. In humans, imprinted expression of
IGF2R appears to be absent fromall tested adult tissues [11,12]. However,
human IGF2R, SLC22A2 and SLC22A3 all show a polymorphic and
concordant form of imprinted expression in placenta in approximately
40% of informative samples [7]. Polymorphic imprinting of IGF2R has
also been seen in early fetal tissue, cultured amniotic cells, lympho-
blastoid cells andWilms' tumors [13–16]. However, the imprinted status
of human IGF2R remains controversial as some studies showa complete
lack of imprinted IGF2R expression in fetal tissues [17] and some
publications refer to human IGF2R as a non-imprinted gene [18].
Imprinted expression of the mouse Igf2r, Slc22a2 and Slc22a3 genes
is caused by paternal-speciﬁc expression of the Air ncRNA. Imprinted
expression of Air itself, is caused by a DNAmethylation imprint acquired
during oocyte development that silences the maternal Air promoter
[19]. Mouse Air expression is driven by a CpG island promoter in Igf2r
intron 2, that is antisense to the Igf2r promoter thus the Air ncRNA
overlaps the 5′ part of Igf2r. The Air ncRNA does not overlap the two
other genes it silences [20]. The mouse Air ncRNA is an unusual RNAPII
transcript that evades cotranscriptional splicing, resulting in a mature
108 kb ncRNA that is nuclear localized and relatively unstable [21].
The human IGF2R gene also contains a CpG island in intron 2 that
carries a similar maternal-speciﬁc DNA-methylation imprint in all
tested fetal and adult tissues [15,22]. However, no evidence of a
human AIR transcript has been found [13]. Since CpG islands strongly
correlate with promoter predictions [23], we test here the ability of
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transfection assays, and, in vivo in transgenic mice. The results show
that the human IGF2R intron 2 CpG island is a promoter that produces
a ncRNA orientated antisense to human IGF2R. Moreover, we use the
transgenic human cDNAs to design RT-PCR assays that identiﬁed the
same ncRNA at the endogenous human locus in 16–40% of human
Wilms' tumor samples. The transcriptional start site of the endogen-
ous human AIR ncRNA was mapped in Wilms' tumors samples and
shown to coincide with a DNase1 hypersensitive site present only on
the unmethylated paternal intron 2 CpG island. The presence of a
DNase1 site at the endogenous human locus that indicates open
chromatin, together with the demonstration that the human IGF2R
intron 2 CpG island can be an active promoter in transfection and
transgene assays, indicates that lack of AIR expression in human
tissues may result from the absence of essential transcription factors
for this ncRNA promoter.
Results
Promoter activity of the human IGF2R intron 2 CpG island in transfection
assays
Transient transfection assays were performed in two human cell
lines using fragments from the human IGF2R intron 2 CpG island (here
called CGI-2) subcloned into the pGL3 expression vector. Six reporter
constructs (Fig. 1A), containing a SV40 enhancer plus different lengths
of CGI-2 sequences were tested for promoter activity. Of all human
fragments, only a 777 bp BstXI fragment and an overlapping 1439 bp
BssHII–BglII fragment (X83701/3344–4121 bp and X83701/3359–
4798 bp) showed signiﬁcant Luciferase activity in HeLa cells (Fig.
1B). Similar activity was shown by a control mouse Air promoter
(mmAP). No promoter activity was detected from a 1578 bp BssHII–
BamHI fragment also spanning the promoter region. No fragment had
promoter activity in HS27 human foreskin ﬁbroblasts (Fig. 1C), or in
mouse NIH3T3 ﬁbroblasts (data not shown). These results show that
sequences immediately upstream of human CGI-2 have promoter
activity in some cell types.
Promoter activity of the human IGF2R intron 2 CpG island in mouse
transgenes
To test expression of human CGI-2 in a normal chromatin
environment and validate the transient expression studies, mouse
transgenes carrying human CGI-2 were generated. Two transgenic
constructs: Human Region 2 Long (HR2-L) and Human Region 2 Short
(HR2-S) were generated (Fig. 2A). HR2-L contained a 5383 bp human
CGI-2 fragment that included the region identiﬁed above showing
transient promoter activity, joined to a 1.2 kb polyadenylation signal
orientated to terminate the predicted AIR transcript. HR2-S is identical
except for a shorter polyadenylation cassette. Nine mouse transgenic
lines representing nine independent integration sites with transgene
copy numbers ranging from 4 to 25 were generated by oocyte
injection (Fig. 2B). Two transgenes (HR2-L2 and HR2-L8) did not
transmit through the germ line and expression was analyzed in
founder (F0) mice. Of the remaining 7 transgenic lines, all were free of
methylation after transmission through the maternal and paternal
germ line and 8/9 transgenes expressed a human CGI-2 transcript (Fig.
2B, and data not shown).
Human CGI-2 expression analyzed by Northern blot of adult mouse
brain showed expression of three different sized transcripts (Fig. 2C).
A 0.5 kb transcript in lines HR2-L7, HR2-L5 and HR2-L4, a 1.0 kb
transcript in line HR2-L3, and a 4.0 kb transcript in line HR2-S2. Line
HR2-S2 also expressed the 4.0 kb transcript strongly in spleen and
weakly in uterus (Fig. 2D). Six transgenic lines (HR2-S2, HR2-L3, HR2-
L4, HR2-L5, HR2-L6, HR2-L7) were tested for imprinted human CGI-2
expression in 13.5dpc embryo, placenta and adult mouse tissues. Alltransgenes were equally expressed following maternal and paternal
transmission and thus lacked imprinted expression, as shown for
HR2-L3 and HR2-L5 (Fig. 2E, F). Line HR2-L3 expressed all three RNA
isoforms (0.5, 1.0, 4.0 kb) in a tissue-speciﬁc fashion that were all
similarly expressed uponmaternal and paternal transmission (Fig. 2E).
Line HR2-L5 expressed only the 1.0 kb isoform on maternal and
paternal transmission. Notably, although the above transient expres-
sion studies showed no expression from a 1578 bp fragment, mouse
transgenes that included this region were expressed when inserted in
6 independent integration sites. In summary, the results show that in
embryonic and adult tissues in transgenic mice the human CGI-2 is an
active non-imprinted promoter.
Transgenic human CGI-2 produces spliced and unspliced transcripts
Northern blots in Fig. 2 identiﬁed various sized human CGI-2
transcripts indicating alternative splicing. We have previously shown
that the mouse Air ncRNA is an unusual RNAPII promoter that
produces predominantly unspliced 108 kb transcripts and a small
percentage of spliced transcripts that appear to be non-functional
[21]. The processing of human CGI-2 transcripts was investigated by
RT-PCR and sequencing using multiple primers shown in Fig. 3A. Two
spliced variants (AIR SVI, Accession No. DQ220010 and AIR SVII,
Accession No. DQ220011, Sup. Fig. 1) were identiﬁed in mice carrying
the HR2-L transgene construct. Both spliced variants used the same
human CGI-2 exons 1 and 2 as well as the splice donor/acceptor in the
β-globin polyadenylation cassette, however, SVII contained an addi-
tional human CGI-2 exon (Fig. 3A and data not shown). Evidence for
unspliced human CGI-2 transcripts was also obtained from primers 1r/
1f that ampliﬁed a 281 bp fragment in both transgene types (data not
shown). The presence of unspliced human CGI-2 transcripts is
suggested from the abundant 4.0 kb signal in Northern blots shown
in Fig. 2, that is similar to the length of transgene DNA downstream of
sequences showing transient promoter activity. The unspliced 4.0 kb
cDNA was the only isoform seen in HR2-S2 transgenes carrying the
shorter polyA cassette.
RNase Protection Assays (RPA) were used to identify the orienta-
tion of human CGI-2 transcripts. The HB antisense probe recognized a
speciﬁc 120 bp fragment in transgenic RNA samples corresponding to
the opposite strand encoding IGF2R (Fig. 3B, left). Transcription in the
opposite direction was not seen (Fig. 3B, right). RPA was also used to
show the relative abundance of the spliced to unspliced human CGI-2
transcripts, which varied from 4.3:1 to 2.1:1 (Fig. 3C). Note that in the
mouse, spliced Air transcripts are more stable than unspliced
transcripts [21].
Sequence analysis of the spliced variants and of unspliced human
CGI-2 transcripts (http://repeatmasker.org, http://www.ncbi.nlm.nih.
gov/projects/gorf/) shows they contain 30% interspersed repeats and
lack a continuous open reading frame longer than 120 bp, indicating
that all are non-coding (Sup. Fig. 1 and data not shown). These results
show that human CGI-2 transgenes can express both unspliced and
spliced non-coding transcripts from the DNA strand opposite to IGF2R.
Human CGI-2 transcripts are here named AIR (Antisense IGF2R RNA)
to correspond with the mouse name.
Transgenic human CGI-2 transcriptional start sites
Two transcriptional start sites were identiﬁed in mouse brain for
line L7 (Fig. 3D). T1 (Accession No. DQ220013) is located 721 bp
upstream of human CGI-2 at position 3904 bp in X83701. T2
(Accession No. DQ220014) is located further upstream at position
4377 bp in X83701 (Sup. Fig. 1). Both T1 and T2 lie within the 0.7 kb
fragment with promoter activity identiﬁed in Fig. 1. T1 was identiﬁed
in all tested transgenic lines (Fig. 3E) while T2 was only seen in L7 and
S2. Active transcription originating upstream of T2 was also identiﬁed
but this was shown not to arise from an upstream start site but from
Fig.1.Human CGI-2 promoter activity in transient transfection assays. (A) 630 kbmap fromhuman Chr.6 including IGF2R (http://genome.ucsc.edu, Human Build 36.1 assemblyMarch
2006). CpG islands indicated by bars — CpG-99 (circled) is a 1238 bp CpG island located in IGF2R intron 2 (160,346,255–160,347,492) that contains 99 CpG dinucleotides with a 0.66
CpG:GpC observed:expected ratio. A map of IGF2R intron 2 is shown underneath, the direction of the IGF2RmRNA is indicated and exons 2 and 3 by black boxes. The position of CpG-
99 (identiﬁed using CpG plot, http://www.ebi.ac.uk/servicestmp/cpgplot) within IGF2R intron 2, is indicated by a black line. A 768 bp region within CpG-99 that contains a series of
Tandem Direct Repeats (TDR) is indicated by the grey box marked with arrowheads. The lines underneath show the fragments used in transient transfection analyses. Clone pE3up
(X83701) contains a 5.741 kb fragment from intron 2 of IGF2R and was used to prepare ﬁve fragments to test for transient expression after subcloning into the pGLE3 vector (Sac1/
639 bp, BstXI/777 bp, BssHII–BglII/1439 bp, BssHII–BamHI/1578 bp, SacI/1667 bp). The EcoRI–SpeI fragment was used to prepare transgenic constructs shown in Fig. 2. The predicted
orientation of AIR antisense transcripts is shown underneath. (B–C) Luciferase activity after transfection in HeLa and HS27 human ﬁbroblast cells. Activity of the control pGL3E vector
without promoter was set to 1. Results are shown for the pGL3E vector plus control promoters (Sv40 andmouse Air promoters: Sv40P andmmAP) or plus the test human IGF2R intron
2 CpG island fragments shown above. Note that fragment BstXI (777 bp) was assayed in sense (777 bp) and antisense (777 bpas) orientation. ⁎⁎Statistically signiﬁcant (pb0.001)
promoter activity. The mean values of two biological replicates, each performed in ﬁve technical replicates, are shown.
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summary, the human AIR ncRNA has at least two transcriptional starts
sites that lie upstream to the CpG island in CGI-2 transgenes.
Non-coding AIR transcripts at the endogenous human IGF2R intron 2
CpG island
The human CGI-2 mouse transgenic expression pattern raised the
possibility that the endogenous human IGF2R intron 2 CpG island
would also contain an active promoter for an antisense AIR ncRNA.We
ﬁrst examined the EST database for evidence of expression (www.
ensemble.org, March 2006 human genome sequence build 36.1Chr.6:160,230,000–160,340,000). Eight ESTs were found within the
human IGF2R intron 2 CpG island just downstream to the AIR
promoter identiﬁed in the above transgenic/transfection experiments
(Sup. Fig. 2A). These comprised a single thymus EST (AW008515)
corresponding to an unspliced AIR ncRNA transcript and seven RAGE
(Random Activation of Gene Expression) ESTs (BG182740, BG196263,
BG216625, BG209200, BG191601, BG186411, and BG216164) obtained
from a promoter insertion screen [24]. All seven RAGE clones used the
same splice acceptor site at the start of human AIR exon 2 identiﬁed in
the transgenic experiments (position 1872 bp in X83701) which
indicates that the exon 2 splice acceptor identiﬁed in the transgene
experiments is functional in the human genome. Examination of the
Fig. 2.Human CGI-2 transgenic mouse constructs. (A) Map of human CGI-2 constructs used to create transgenic mice. HR2-L: a single LoxP1 site (black circle), a 1.2 kb rabbit β-globin
polyA cassette that contains exon 3, intron 2 and the 3′ end of exon 2 (grey bar with exons as grey boxes), 13 bp of vector sequence and 1–5384 bp (EcoRI–SpeI) from X83701. HR2-S
differs in length of the polyA cassette that is reduced to 0.5 kb and only contains the 3′ end of exon 3 and thus lacks any splice acceptors.White box; the 1439 bp BssHII–BglII fragment
with promoter activity identiﬁed in Fig. 1. SVI probe; the human spliced AIR transcript used as a Northern blot probe in C. BstXI; the fragment used for Southern blots in B. Grey bar
with arrowheads; 768 bp region shown in Fig. 1A containing tandem direct repeats. Grey circle labeled Ap; polyA signal orientated to terminate the predicted AIR transcript. (B) Table
showing methylation and expression status of human CGI-2 in 9 transgenic lines. TG-Line; transgenic mouse line, Copy No; transgene copy number (see methodsMaterials and
methods), Mat-meth and Pat-meth; methylation upon maternal and paternal transmission (see Materials and methods), Mat-exp and Pat-exp; expression upon maternal and
paternal transmission (C). nt; not transmitted through germline. F0; founder generation. (C) Northern blots showing expression of 3 human CGI-2 transcripts (4 kb,1 kb and 0.5 kb) in
adult brain from different transgenic lines, using probe SVI. Mouse Gapdh was used as a loading control. L7; HR2-L7, L5; HR2-L5, L4; HR2-L4, S1; HR2-S1, wt; wildtype brain, L3; HR2-
L3, S2; HR2-S2. (D) Northern blot of adult S2 transgene organs showing tissue-speciﬁc expression in spleen and brain of a 4 kb human CGI-2 transcript. 1; liver, 2; lung, 3; kidney, 4;
spleen, 5; uterus, 6; brain, 7; wild type brain. (E) Northern blot of paternal (HR2-L3-Pat) and maternal (HR2-L3-Mat) expression in adult HR2-L3 transgenic organs showing a lack of
imprinted expression. Lung (lane 2, 4 kb transcript) and heart (lane 3,1.5 kb transcript) showed variation betweenmaternal and paternal blots that was not reproducible and reﬂects a
loading variation. Lanes 1; liver, 2; lung, 3; heart, 4; kidney, 5; testis (4 kb transcript), 6; spleen (0.5 kb transcript), 7; brain (1.5 kb transcript), 8; wildtype brain. ⁎non-speciﬁc band. (F)
Northern blot of paternal (HR2-L5-Pat) andmaternal (HR2-L5-Mat) expression in adult HR2-L5 transgenic organs showing a lack of imprinted expression. Theweak expression in the
kidney sample (lane 4, 0.5 kb transcript) showed variation betweenmaternal and paternal blots that was not reproducible and reﬂects a loading variation. Lanes wt;wildtype brain,1;
liver, 2; lung, 3; heart, 4; kidney, 5; testis (0.5 kb transcript), 6; spleen, 7; brain (0.5 kb transcript).
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MAS1 gene that corresponds to the mouse Air transcription unit,
identiﬁed 15 human ESTs many of which are expressed in the nervous
system, that are putative AIR partial cDNAs (Sup. Fig. 2B).We next used RT-PCR to test for spliced non-coding AIR transcripts
in Wilms' tumors, previously reported as showing polymorphic IGF2R
imprinted expression [9]. Primer pair pp9 that spanned exons 1–2 of
the transgenic human AIR ncRNA ampliﬁed the correct 160 bp
Fig. 3. Human CGI-2 transgenes express spliced and unspliced transcripts. (A) Human CGI-2 transcripts analyzed by RT-PCR for HR2-L (top box) and HR2-S (lower box) transgenes. A
transgenemap is shown above (details as in Fig. 2A) with primer locations. T1, T2 indicate the sequence identiﬁed by 5′RACEwith primers 2f+4f, as transcriptional start sites (D). Grey
bars indicate ESTs in this region (http://genome.ucsc.edu) see Sup. Fig. 2. The position of splice variants SVI and SVII identiﬁed by primers Ap+3r, is shown. Introns are indicated by
grey lines, exons by numbered black bars. The dashed bar indicates the predicted unspliced AIR transcript corresponding to the 4 kb Northern blot signal in Fig. 2C. Black bars within
this indicate unspliced AIR transcripts detected with primers 1r, 1f and HC RPA probe. HC1/HC2 and HB1/HB2: primers used to prepare RNase protection probes. (B) RNase protection
assay with probe HB in brain samples from adult transgenic mice showing expression of spliced human CGI-2 transcripts. The probe HBas protects transcripts with the opposite
orientation to IGF2R and identiﬁes a 120 bp spliced SVI and SVII transcript (labeled AIR, present in lanes 4–6), and a 199 bp unspliced transcript (not distinguishable from a non-
speciﬁc product⁎⁎). Probe HBs protect a 120 bp product with the same orientation to IGF2R and fails to identify any transcripts from the human CGI-2. An in vitro transcribed 140 bp
fragment from probe HBas is used as a positive control for the HBs probe (⁎lane 9). Mouse Cyclophilin A (protecting 105 bp) was used as a loading control. 1; marker, 2,3; yeast RNA
controls minus/plus RNase treatment, 4; HR2-L4 brain, 5; HR2-L6 brain, 6; HR2-L3 brain, 7; HR2-L5 brain, 8; wild type brain. (C) RNase protection assay with probe HC in adult HR2-
L3 transgenic organs showing relative abundance of spliced and unspliced human CGI-2 transcripts. The probe protects 121 bp spliced AIR transcript in lanes 5–8 (the band is weak in
lane 5), and a 260 bp unspliced AIR transcript in lanes 5–8 (the band is weak in lane 5). Mouse 18S probe (protecting 80 bp) was used as a loading control. 1; marker, 2; HC probe, 3;
yeast controls minus RNase, 4; liver, 5; lung, 6; brain, 7; heart, 8; testis, 9; kidney, 10; wild type testes control, 11; wild type kidney control. (D) Identiﬁcation of human AIR
transcriptional start sites in HR2-S2 transgenic mice by 5′RACEwith gene speciﬁc primers 2f and 4f. Lane 1; minus phosphotase control, lane 2; plus phosphotase, lane 3; no template.
T1, T2; transcription start site 1 and 2. (E) T1 and T2 start sites in human CGI-2 transgenic mice. nd; not done.
468 I.Y. Yotova et al. / Genomics 92 (2008) 464–473fragment from 1 in 3 tested Wilms' tumors cell lines (Fig. 4B). This
fragment was sequenced to show it arose from a correctly spliced
human AIR ncRNA (data not shown). We used 5′RACE to identify the
endogenous human AIR ncRNA transcriptional start in the STA-WT3ab
Wilms' tumors cell line. A single transcriptional start site was
identiﬁed, identical to the T1 site used in the human CGI-2 transgenes
(Fig. 4C). Next, we assayed spliced human AIR ncRNA in two sets ofWilms' tumors tissue samples (Fig. 4D). In Set 1 comprising 31Wilms'
tumors and related non-tumor samples, respectively 16.1% and 12.5%
were positive. In Set 2 comprising 120 Wilms' tumors, 42.5% were
positive. In the majority of Wilms' tumors samples the ampliﬁed
spliced AIR product was seen as a relatively weak band, only a few
samples produced a strong PCR band (Sup. Figs. 3,4). This indicates
that while the human IGF2R intron 2 CpG island can function as a
Fig. 4. Spliced and unspliced AIR transcripts at the endogenous human locus. (A) Map of part of human chromosome 6q27 showing IGF2R and ﬂanking genes (dark grey boxes) with
transcription orientation indicated by arrows and the human CGI-2 marked by an asterisk. Primers and QPCR assays are indicated underneath (details in Sup. Table 1). (B) Expression
of spliced AIR by RT-PCR using primer pair pp9 in humanWilms' tumor cell lines (lane 1: Sk-Nep1-negative, lane 2: G-401-negative, lane 3:STA-WT3ab-positive for a 160 bp product)
and lane 4: HS27 human foreskin ﬁbroblasts. Plasmid SV1 containing the spliced human AIR product frommouse transgenes was used as a positive control. Human GAPDHwas used
as loading control. N; negative control PCR reaction without template. (C) Identiﬁcation of the endogenous human AIR transcriptional start site in STA-WT3ab Wilms' tumor cells by
5′RACE with primers 2f and 4f. Lane 1; minus phosphotase control, lane 2; plus phosphotase, T1; transcription start site 1. (D) Summary of expression of spliced AIR by RT-PCR using
primer pair pp9, in two sets of Wilms' tumor samples (see Sup. Figs. 3,4). Set 1 comprises successively accessioned cases ofWilms' tumor seen at Columbia University Medical Center
that were not selected for any particular tumor stage or characteristics. The samples were from primary nephrectomy without pre-operative chemotherapy. Set 2 are Wilms' tumor
samples from the German SIOP/GPOH 93-01 study and represent a largely unbiased series of tumors, predominantly with pre-operative chemotherapy as mandated by the European
protocol. (E) Quantitative RT-PCR analysis of unspliced AIR (AIR QPCR1 assay) and IGF2R (IGF2R QPCR assay) expression in human Wilms' tumor cell lines — 1; Sk-Nep1, 2; G-401, 3;
STA-WT3ab, and 4; HS27 cells, using assays shown in A. Values average three technical replicates normalized to GAPDH.
469I.Y. Yotova et al. / Genomics 92 (2008) 464–473promoter for the AIR ncRNA, its expression may be restricted to a
subpopulation of cells in the tested samples.
Since expression of the mouse Air ncRNA correlates with silencing
of one parental Igf2r allele we used QPCR to test if there was a
correlation between high expression of the human AIR ncRNA in
Wilms' tumors and low expression of IGF2R. We were not able toperform an allele-speciﬁc assay of human IGF2R in these samples as
matched genomic DNA was not available. We ﬁrst assayed AIR and
IGF2R in three Wilms' tumors cell lines. Fig. 4E shows that AIR is
expressed only in the STA-WT3abWilms' tumor cell line, and that this
cell line shows the lowest expression of IGF2R. We then applied the
same assay toWilms' tumor samples that expressed no AIR, or showed
470 I.Y. Yotova et al. / Genomics 92 (2008) 464–473medium AIR expression or high AIR expression as judged from the
non-quantitative PCR data shown in Sup. Fig. 4A. Samples with no or
medium AIR expression showed no correlation between AIR expres-
sion and reduced IGF2R expression while 3/6 samples with high AIR
expression showed reduced IGF2R expression. (Sup. Fig. 4B). Thus the
data do not show a clear correlation between human AIR expression
and reduced IGF2R expression as shown for the mouse Igf2r imprinted
gene cluster [19]. However, since Wilms' tumor samples most likely
contain mixtures of cells only some of which express AIR, the data do
not exclude a correlation between expression of the AIR ncRNA andFig. 5. The unmethylated human IGF2R intron 2 CpG island contains a DNase1 hypersensit
transcription. A map of the fragment used to generate the mouse transgenes is shown unde
cluster of tandem direct repeats (TDR) within this island is shown. The BstXI probe used in the
indicated. The paternal-speciﬁc DHS site identiﬁed in B, is markedwith a resolution of ±500 b
from HS27 human foreskin ﬁbroblast cells treated with different concentrations of DNase1, d
nuclei treated either with incubation buffer at 37 °C or left on ice. Samples treated with DNase
of this DNase1 hypersensitive site can be determined with a resolution of ±500 bp to be at
(indicated above in A). The middle and lower panel shows Southern blots frommouse A9 cell
parent (HS6-MAT) or from the paternal parent (HS6-PAT) [25], treated as described for A. The
containing the paternal chromosome. (C) DNAmethylation of the IGF2R intron 2 CpG island is
2 bands, one from the maternally-methylated allele (5.7 kb) and one from the unmethylat
imprint on the maternal copy of the IGF2R intron 2 CpG island (5.7 kb), while HS6-PAT have
(data not shown and [25]).silencing of IGF2R in cis. Further experiments using homogenous cell
populations or single cell assays will be needed to test if human AIR
can silence IGF2R in cis.
A DNase1 site marks the unmethylated human IGF2R intron 2 CpG
island
DNase1 hypersensitive (DHS) sites identify short regions sensitive
to nucleases because of nucleosome displacement, which are often
binding sites of transcription factors and thus likely to be cis-actingive site. (A) Map of human IGF2R intron 2 (17.686 kb) showing the direction of IGF2R
rneath. The length of the intronic CpG island (CpG 99) is indicated and the location of a
Southern blots in B,C is shown. The transcription start sites T1, T2, mapped in Fig. 3A are
p. (B) Identiﬁcation of a paternal-speciﬁc DNase1 hypersensitive site. Top: Southern blot
igested with EcoRI and hybridized with probe BstXI. The last two lanes contain control
1 show a second 2.5 kb band in addition to the expected 5.7 kb EcoRI band. The position
the border between the 1440 bp fragment with promoter activity and the CpG island
s containing a full mouse genome plus a single human chromosome 6 from the maternal
2.5 kb band produced by treatment with DNase1 is only present in somatic cell hybrids
maternal-speciﬁc. HS27 cells contain maternal and paternal chromosomes and produce
ed paternal allele (2.9 kb). HS6-MAT somatic cell hybrids retain the DNA-methylation
a methylation-free island (2.9 kb). The HS6-PAT somatic cell hybrid lacks AIR expression
471I.Y. Yotova et al. / Genomics 92 (2008) 464–473regulatory elements such as promoters or enhancers. We tested if the
endogenous human IGF2R intron 2 CpG island contained a DHS site in
HS27 normal diploid human ﬁbroblasts, which lack AIR expression as
shown in Fig. 4B. Fig. 5A shows a map of the tested region and the
position of the human IGF2R intron 2 CpG island. A strong DHS site
was identiﬁed in HS27 cells that mapped to a ∼500 bp region between
the CpG island and the major transcription start T1 identiﬁed in
transgenic studies and in Wilms' tumors (Fig. 5B). Moreover, analysis
of somatic-cell-hybrid cell lines containing either a paternal or a
maternal human Chr.6 (that contains IGF2R) on a mouse background
[25], shows that this DHS site is found only on the paternal
chromosome. Fig. 5C shows that the paternal copy of human Chr.6
lacks a methylation imprint present over the human IGF2R intron 2
CpG island on the maternal chromosome. Thus, the paternal human
IGF2R intron 2 CpG island lacks DNA methylation and contains a
DNase1 hypersensitive site indicating a potential for expression.
Discussion
Here we have tested if the human IGF2R gene that shows
polymorphic imprinted expression is able to express an antisense
ncRNA from a CpG island located in intron 2. Studies from the mouse
imprinted Igf2r gene has shown that the antisense Air ncRNA, which is
expressed from a homologous intron 2 CpG island, is directly
responsible for silencing Igf2r and the ﬂanking Slc22a2 and Slc22a3
genes in cis [19]. We used transfection and mouse transgenic assays to
demonstrate that the human IGF2R intron 2 CpG island has promoter
activity. Moreover, this promoter can express an antisense ncRNA that
we name AIR in agreement with the mouse nomenclature [20], in both
mouse transgenes and in Wilms' tumors. The mouse transgenes were
an essential tool to localize human AIR expression as previous studies
based on random RT-PCR assays throughout the 99 kb region
corresponding to the mouse Air transcript (from IGF2R intron 2 —
MAS1), failed to identify AIR transcription [13]. Our demonstration that
the human IGF2R intron 2 CpG island is an active promoter is supported
by the identiﬁcation of RAGE EST clones that use the splice acceptor of
human AIR exon 2 [24], and by our identiﬁcation of a DNase1
hypersensitive site that is often associated with cis-regulatory elements
[26], which is only present on the unmethylated paternal allele.
The human IGF2R intron 2 CpG island was previously known to
show three similarities to the homologous mouse Igf2r intron 2 CpG
island that controls imprinted expression of the mouse Air ncRNA.
These similar features are; that both lie in the second IGF2R/Igf2r
intron close to exon 3, both are modiﬁed by a DNA-methylation
imprint only on the maternal chromosome and both lie in a
chromosomal region showing asynchronous behavior in S-phase
cells [15,22]. The results presented here identify a fourth similarity in
that both the human and mouse IGF2R/Igf2r intron 2 CpG islands, can
act as promoters for the AIR/Air antisense ncRNA. We further show
that the human AIR ncRNA is expressed in 16–40% of Wilms' tumors
and that high expression of the AIR ncRNA correlates in 3/6 tumor
samples, with reduced IGF2R expression. These data indicate that the
human IGF2R imprinted gene cluster which also includes the SLC22A2
and SLC22A3 genes that only show imprinted expression in placenta
[7], shows evolutionary conservation of the key features that control
imprinted expression in the mouse.
Polymorphic imprinted expression of the human IGF2R gene cluster
The human IGF2R–SLC22A2–SLC22A3 gene cluster shows a con-
cordant but polymorphic form of genomic imprinting, in which only a
subset of tested samples show imprinted expression and at this stage
of our knowledge, this behavior appears to be limited to fetal tissues
and Wilms' tumors [7,13,14,16]. In contrast to polymorphic imprinted
expression, the DNA-methylation imprint is always present on the
maternal copy of the human IGF2R intron 2 CpG island in all cells of anindividual [15,22,27,28]. Thus, human cells carry a methylation
imprint on the IGF2R intron 2 CpG island that in most cases does
not lead to imprinted expression. In the mouse, the maternal-speciﬁc
methylation imprint on the Igf2r intron 2 CpG island is used to repress
the Air ncRNA that is the key silencer of this gene cluster [19,21].
However, the mouse Igf2r gene can also separate the presence of the
methylation imprint from imprinted expression, by regulating Air
ncRNA transcription. For example, mouse preimplantation embryos,
ES cells and post-mitotic neurons show bi-allelic Igf2r expression in
the presence of the maternal methylation imprint because they lack
Air expression [9,29,30,31]. This indicates that polymorphic imprinted
expression of the human IGF2R imprinted gene cluster could be
explained by a differential ability to transcribe the AIR ncRNA
promoter in the human population, most likely arising from regula-
tion of essential trans-acting factors.
Human IGF2R intron 2 CpG island is a typical CpG island promoter
CpG islands, deﬁned as regions with a higher CpG content than the
genome average, are themost reliable feature for gene-prediction in the
mammalian genome and are associatedwith 60% of promoters [32]. The
human IGF2R intron 2 CpG island contains consensus CG-rich transcrip-
tion factor binding sites, such as SP1, AP1 and GATA that are mainly
clustered between the 3′ end of the island and the T1 transcription start
site (data not shown). The main human AIR transcription start site was
mapped 721 bp upstream of the CpG island. We also precisely
determined the start sites of the endogenous mouse Air promoter to
be at the 5′ border of the CpG island (data not shown). Thus, for both the
mouse and the human intron 2 promoters, the bulk of the CpG island is
internal to the transcribed ncRNA and the mapped promoters lie
upstream. Previously, promoters were considered to be part of the CpG
island [23]. The internal position of the AIR/Air CpG islandsmay indicate
they act as cis-regulators such as enhancers, rather than promoters. The
expression pattern of human CGI-2 transgenes was different to that
shown by the mouse Air ncRNA. Human CGI-2 constructs were
expressed in most transgenic lines and were highly expressed in adult
brain, testes and a few other tissues but lowly expressed in adult heart.
Mouse Igf2r intron 2 CpG island transgenes have a similar ability to be
expressed as a transgene, but they show highest expression in adult
heart that is typical of the endogenous transcript [33]. The human CGI-2
transgenes did not acquire a maternal-speciﬁc methylation imprint,
however, this feature is also absent from the similar-sized mouse
transgenes [33,34]. The lack of a methylation imprint in human CGI-2
transgenes explains expression following maternal and paternal
transmission, as the methylation imprint is necessary for imprinted
expression in mice [21,35].
Functional consequences of polymorphic human IGF2R imprinted
expression
The IGF2R gene is a non-transducing intracellular transport
receptor with multiple growth-suppressor functions, that include
activation of the TGFβ growth suppressor and degradation of the IGF2
growth factor [36]. There is now a growing list of human tumors that
show reduced IGF2R function as a consequence of genetic changes
arising from genomic instability of the FRA6E fragile site that spans a
3.6 Mb region containing IGF2R [37], mutations of mismatch repair
enzymes [38], or, inactivating mutations in coding regions of the gene
[39]. In many cases these genetic mutations are accompanied by loss
of the other parental allele (known as loss of heterozygosity) and
IGF2R is now designated as a tumor suppressor gene [40].
Polymorphic imprinted expression of the human IGF2R gene has
only been observed in fetal and tumor tissues [7], while adult tissues
would normally express IGF2R from both the maternal and paternal
allele [17,18]. However, in view of our demonstration here that the
human IGF2R intron 2 CpG island contains an active AIR promoter, a
472 I.Y. Yotova et al. / Genomics 92 (2008) 464–473scenario could be envisagedwherebygain of paternal expression of the
AIR ncRNAwould lead to silencing of the paternal IGF2R allele, even in
adult tissues. Thus, reduced IGF2R function could theoretically arise in
tumors epigenetically, as a consequence of a gain of imprinted gene
silencing. Changes in the imprinted status of the IGF2 growth factor
have been described in many tumor types, however, in this case IGF2
shows a loss of imprinted expression with aberrant activation of the
normally silent maternal allele [41]. Nonetheless, there are precedents
for a form of epigenetic silencing in human disease and tumors that is
dependent on expression of antisense ncRNA [42]. For example, a
Thalassaemia has been identiﬁed that results from a de novo
transcriptional overlap of the alpha globin gene [43], and silencing of
the p15 (CDKN2B) tumor suppressor gene in leukemia correlates with
gain of expression of an antisense ncRNA that overlaps the promoter
[44]. We have shown here that the human IGF2R gene contains an
intronic CpG island promoter that expresses the AIR ncRNA in mouse
transgenes and in Wilms' tumors. In mice, experiments have shown
that the Air ncRNA can silence all three gene in the imprinted Igf2r
gene cluster [19]. Our results here do not show a clear correlation in
Wilms' tumors between high AIR expression and reduced IGF2R
expression. However, they do not exclude this possibility. Further
experiments using homogenous cell populations or single cell assays
will be needed to test the consequence of human AIR expression on the
downstream IGF2R promoter to determine if gain of AIR expression
could provide an epigenetic mimic of the genetic changes leading to
loss IGF2R function in tumors.
Materials and methods
Transient transfection assays
DNA fragments were subcloned into pGL3-Enhancer vector
(Promega) (from X83701: 639 bp SacI fragment bp3434–4073,
777 bp BstXI fragment bp3344–4121, 1439 bp BssHII–BglII fragment
bp3359–4798,1578 bp BssHII–BamHI fragment bp3359–4937,1667 bp
SacI fragment bp4074–5741, from AJ249895: 1105 bp PstI–EcoRI
fragment bp126132–127237) and assays were performed as described
[20]. Transfections were performed ﬁve times and repeated with two
different DNA preparations.
Transgenic constructs and transgenic mice
Construct HR2-L contains a 5384 bp human fragment (X83701
1–5384 bp) upstream to a 1200 bp polyadenylation cassette (rabbit
β-globin, 31392–32590 bp/M18818) and LoxP1 (oligonucleotides 5′-
AGCTTATAACTTCGTATAATGTATGCTATACGAAGTTATG and 5′-TCGA-
CATAACTTCGTATAGCATACATTATACGAAGTTATA). 13 bp of vector
backbone remained between the human fragment and the polyA
cassette including an EcoRV site. Construct HR2-S differs from
construct HR2-L only in the length of the polyA cassette (32033–
32590 bp/M18818) that includes the polyA signal but lacks the last
intron. The polyA signal was orientated to terminate the predicted
AIR antisense transcript. Transgenic mice were generated by
injecting DNA into B6/CBA fertilized oocytes using standard
procedures. Transgenes were bred onto a FVB background and
identiﬁed by DNA analysis.
Methylation analysis
Tail DNA from transgenic mice was extracted, digested with
methyl-sensitive enzymes HpaII or NotI in combination with HindIII
using standard methods. Hybridization probe BstXI (577 bp BstXI
fragment from X83701). Complete digestion was veriﬁed with HTF9c
probe that contains an unmethylated CpG island (NM_008307).
Transgene copy number was determined by hybridization of EcoRV
digested DNA with probe BstXI.DNase1 assay
Tissue culture cells (107–108) were trypsinized into a single cell
suspension. The preparation of nuclei and the DNase1 (Roche) digest
were as previously described using a concentration range from 90–
1000 U/ml [45]. DNase1 treated DNA was prepared and analyzed by
Southern blot using standard protocols.
RNA analysis
5′RACE
Total RNA and polyA+ RNA prepared by RNAwizTM (Ambion) was
analyzed using the First-Choice® RLM-RACE kit (Ambion) and primer
2f (external) and 4f (internal) for 35 cycles. PCR products (T1,
DQ220013 and T2, DQ220014) were subcloned and sequenced.
Northern blots
20 μg of total DNase1 (DNA-freeTM, Ambion) treated RNA was
electrophoresed in 1% agarose/formaldehyde gels. Human speciﬁc SVI
probe (EcoRI fragment DQ220010) and mouse speciﬁc Gapdh probes
(BC083149) were used.
Ribonuclease Protection Assay (RPA)
The RPAIII (Ambion) kit was used. The 290 bp HB probe protects
120 bp from the spliced AIR transcript and 149 bp from unspliced AIR
transcript. The 350 bp HC probe protects 121 bp from the spliced and
260 bp unspliced AIR transcript. Mouse Cyclophilin A probe that
protected a 105 bp band and 18S ribosomal gene probe that protected
an 80 bp band were used as loading controls.
Non-quantitative RT-PCR
Reverse transcriptionwas performed on DNase1 treated RNA using
random hexamer primers and RevertAid™ First Strand cDNA Synth-
esis kit (Fermentas). PCRs were performed using a PCR Reagent kit
(Invitrogen) for 32 or 35 cycles. Different splice variants of the human
CGI-2 transgene ncRNA were identiﬁed by RT-PCR using primers Ap
located in exon 3 of the PolyA cassette and primer 3r or 1r. PCR
products were subcloned or directly sequenced.
Quantitative RT-PCR
Assay primers are listed in Sup. Table 1.
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